Freenome
Freenome develops blood tests for early cancer detection using a multiomics platform that combines molecular biology, computational biology, and machine learning. Their tests aim to detect cancer in its earliest, most treatable stages, improving accessibility and convenience of cancer screenings. The company partners with healthcare organizations to integrate its technology and software platform.
Buy Funded Startups lists
Funding Round:
Funding Amount: $254M
Date: 15-Feb-2024
Investors: Roche, a16z Life Sciences Growth Fund, American Cancer Society's BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates, Inc.
Markets: Biotechnology, Healthtech, Health Diagnostics, Personal Health
HQ: Brisbane, California, United States
Founded: 2014
Website: https://www.freenome.com/
LinkedIn: https://www.linkedin.com/company/freenome/
Twitter: https://twitter.com/freenome
Facebook: https://www.facebook.com/freenome
Crunchbase: https://www.crunchbase.com/organization/freenome
Leave a Comment
Comments
No comments yet.